**Core Concept**
HMGCoA reductase is a key enzyme in the biosynthesis of cholesterol, catalyzing the conversion of HMG-CoA to mevalonate. This enzyme is a primary target for cholesterol-lowering medications.

**Why the Correct Answer is Right**
The correct answer is a statin, which is a class of drugs that inhibit HMGCoA reductase. This inhibition leads to a decrease in cholesterol production in the liver, resulting in a reduction in serum cholesterol levels. Statins work by binding to the active site of the enzyme, preventing the conversion of HMG-CoA to mevalonate.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is a class of drugs that actually increase cholesterol production, not decrease it.
**Option B:** This option is incorrect because it is a class of drugs that primarily affect lipid metabolism through a different mechanism, not by inhibiting HMGCoA reductase.
**Option C:** This option is incorrect because it is a class of drugs that primarily affect blood pressure through a different mechanism, not by inhibiting HMGCoA reductase.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that statins are not only used for cholesterol-lowering but also have pleiotropic effects, including anti-inflammatory and antioxidant properties, which can benefit patients with cardiovascular disease.

**Correct Answer: C. Lovastatin**